Drugs / Influenza A (H5N1) Virus Monovalent Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01910519 | Jul 2013 → Feb 2015 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Met primary |
| Phase 2 | NCT00695669 | Jun → Aug 2008 | influenza | GlaxoSmithKline | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Influenza A (H5N1) Virus Monovalent Vaccine | “Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.” NCT01910519 ↗ |
| Known as | GSK 1557484A | “The purpose of the study is to characterize the immunogenicity \& safety of 2 doses of GSK's avian flu vaccine GSK 1557484A given according to different regimens to adults aged...” NCT00695669 ↗ |
| Modality | Vaccine | “GSK's avian flu vaccine GSK 1557484A” NCT00695669 ↗ |
| Route | Intramuscular | “Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.” NCT00695669 ↗ |